A Multi-center, Open-label, Phase I Study of Single Agent R7112 Administered Orally in Patients With Advanced Malignancies, Except All Forms of Leukaemia
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2016
At a glance
- Drugs RG 7112 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Roche
- 02 Mar 2016 Parallel assignment has been removed from study design as per ClinicalTrials.gov record.
- 03 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Apr 2012 Planned end date changed from 1 Jun 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.